GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Apollomics Inc.
The shares of Apollomics, an oncology biotech company, reflect the potential of its drug portfolio. The price trajectory is highly speculative and depends on the results of clinical trials, regulatory decisions, and the company's ability to finance its expensive developments.
Share prices of companies in the market segment - Cancer cure
Apollomics is an oncology company developing targeted drugs and immunotherapies for various types of cancer. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors view this high-risk but potentially disruptive biotech segment.
Broad Market Index - GURU.Markets
Apollomics is an oncology company developing targeted drugs for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Apollomics shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
APLM - Daily change in the company's share price Apollomics Inc.
For Apollomics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials and partnerships, and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Cancer cure
Apollomics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with APLM's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Apollomics is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Apollomics Inc.
For Apollomics, Inc., year-over-year performance tells the story of its oncology pipeline. Its 12-month market cap depends entirely on progress in clinical trials of its targeted drugs. Partnerships with other companies and successful data can fundamentally change its valuation.
Annual dynamics of market capitalization of the market segment - Cancer cure
Apollomics, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Apollomics, a biotech focused on cancer treatment, is a classic bet on a scientific breakthrough. Its year-over-year performance, compared to the market, reflects not the economic trend but the level of investor confidence in its drugs. Research success can drive growth that far exceeds the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Apollomics Inc.
Apollomics is a late-stage oncology company. Its monthly performance is driven by clinical and regulatory events. News about its drug trial results and interactions with the FDA and other regulators are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Cancer cure
This chart reflects the dynamics of the biotech sector, particularly in oncology. For Apollomics, a late-stage company, it's the backdrop. Its movements reflect investor expectations surrounding the potential approval of its drugs, which could be a major event.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Apollomics is a clinical-stage biopharmaceutical company developing cancer treatments. Its value depends almost entirely on the results of clinical trials. The broader market has little impact on Apollomics's stock; its fate is decided in laboratories and clinics, which can lead to sharp movements counter to any market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Apollomics Inc.
Apollomics, an oncology company focused on lung cancer and other solid tumors, is exhibiting the high volatility typical of biotech. Its weekly stock price performance reflects a sharp reaction to clinical trial data and progress in developing its targeted drugs, which target specific mutations.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Apollomics operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether Apollomics is moving with the industry or whether its drug development successes are creating their own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Apollomics, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how Apollomics shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
APLM - Market capitalization of the company Apollomics Inc.
Apollomics's market cap is another focused bet on oncology. This biotech's chart reflects investor expectations for its cancer drug pipeline. Its volatile dynamics are a classic biotech story, where every clinical trial result can dramatically change the valuation.
APLM - Share of the company's market capitalization Apollomics Inc. within the market segment - Cancer cure
Apollomics is an oncology company with a broad portfolio of targeted drugs and immunotherapy candidates. Its sector share reflects this diversified strategy. The chart shows how the market values its various programs and the chances of developing multiple successful cancer drugs.
Market capitalization of the market segment - Cancer cure
Apollomics is a biopharmaceutical company developing targeted drugs for cancer treatment. The chart below shows the market capitalization of the entire oncology sector. This represents the global search for new, more effective, and safer ways to combat various types of tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
Apollomics is an oncology company developing targeted drugs for cancer treatment. Its market capitalization reflects the potential of its research and development pipeline. The chart below shows the economic weight of biotech companies working on smart drugs.
Book value capitalization of the company, segment and market as a whole
APLM - Book value capitalization of the company Apollomics Inc.
Apollomics is based on a portfolio of oncology developments. The company's book value consists of licenses for several drug candidates targeting various cancer types and cash flow for advancing them through clinical trials. The chart below shows how the company manages its diversified, yet risky, research capital.
APLM - Share of the company's book capitalization Apollomics Inc. within the market segment - Cancer cure
Apollomics, Inc., an oncology company, is focused on R&D. Its laboratories are its main physical asset. The S_BCap_Seg chart shows its small share of physical infrastructure, which is typical for a biotech company.
Market segment balance sheet capitalization - Cancer cure
Apollomics is a clinical-stage oncology company. Its future depends on the success of its scientific developments. A book value chart shows that its assets are almost entirely intangible, a classic example for a biotech startup investing all its resources in research.
Book value of all companies included in the broad market index - GURU.Markets
Apollomics' assets comprise a portfolio of oncology drugs targeting Asia. The company's book value reflects its rights to develop several targeted and immuno-oncology drugs. This represents a material and intellectual asset focused on addressing cancer treatment challenges specific to Asian populations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company focused on oncology. Its book value is its cash reserves. Its market capitalization is a valuation of its pipeline of drug candidates and investors' belief in their potential to become new cancer treatments.
Market to book capitalization ratio in a market segment - Cancer cure
Apollomics is an oncology company with a pipeline of drug candidates. Its value is the sum of expectations for these pipelines. The chart shows how the market values this pipeline and its partnerships relative to its book value (primarily cash).
Market to book capitalization ratio for the market as a whole
Apollomics is a biopharmaceutical company developing cancer treatments. Its value depends almost entirely on the success of its clinical trials. The chart demonstrates how the market valuation reflects investors' faith in science and future cash flows, rather than current tangible assets, which is typical for biotech.
Debts of the company, segment and market as a whole
APLM - Company debts Apollomics Inc.
Apollomics, a clinical-stage oncology company, uses debt to finance its broad pipeline of drug candidates. This chart shows how it raises capital to conduct multiple clinical trials simultaneously. This strategy aims to increase the chances of success by diversifying its pipeline.
Market segment debts - Cancer cure
Apollomics is a clinical-stage oncology company focused on developing drugs for the US and Chinese markets. Its financial structure is typical for biotech companies—complete reliance on equity capital to fund lengthy and expensive clinical trials. This chart shows its cash reserves and how quickly they are being burned.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Apollomics Inc.
Apollomics is a biopharmaceutical company specializing in cancer treatments. This chart shows its reliance on debt financing. In oncology, where clinical trials take years and are very expensive, borrowing is a high-risk strategy that reflects confidence in the potential of the drugs being developed.
Market segment debt to market segment book capitalization - Cancer cure
Apollomics, Inc. is a clinical-stage oncology company. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the financial sustainability of a company that does not yet have commercial products or stable revenue.
Debt to book value of all companies in the market
Apollomics is a biopharmaceutical company developing cancer treatments targeting oncogenic drivers. This chart, showing the debt-to-book value ratio, is important for assessing the investment climate in biotech. The market's willingness to finance companies with long development cycles determines Apollomics's ability to raise capital.
P/E of the company, segment and market as a whole
P/E - Apollomics Inc.
Apollomics is an oncology company in clinical trials developing targeted therapy drugs. This chart reflects investor confidence in its scientific pipeline. Its value represents the combined potential of its drug candidates, where the success of even one could lead to multiple price increases.
P/E of the market segment - Cancer cure
Apollomics, Inc. is a biotech company. This chart shows the average P/E for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its oncology drug portfolio compared to the average prospects of other biotech companies.
P/E of the market as a whole
Apollomics is a biopharmaceutical company developing a portfolio of cancer treatments, often in partnership with other companies. Its strategy is to advance several projects simultaneously. This chart shows the mood in the biotech sector. The company's valuation depends on the success of its clinical programs and its ability to effectively manage its diversified portfolio of oncology assets.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company developing cancer treatments. The chart reflects speculative investor expectations. Future revenue is entirely dependent on the success of clinical trials and approvals for its oncology drug candidates.
%20P%2FE%20Apollomics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Apollomics-Inc.&v=1772578489762 "Chart of the company's future (projected) P/E Apollomics Inc.")
Future (projected) P/E of the market segment - Cancer cure
Apollomics is a clinical-stage biopharmaceutical company developing targeted oncology drugs. This chart shows how its future revenue expectations compare to the industry average, reflecting the market's valuation of its pipeline of developments targeting specific mutations in cancer cells.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772578489816 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Apollomics is a clinical-stage biotechnology company developing drugs for the treatment of cancer. Its pipeline consists of several candidates. The company's valuation is the sum of expectations for these projects. It is not linked to general market forecasts but is determined by clinical trial data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772578489847 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Apollomics Inc.
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments targeting specific oncogenic pathways. Its financial performance reflects significant investments in research and clinical trials. This chart illustrates the financial costs of developing a portfolio of innovative anticancer agents.
Profit of companies in the market segment - Cancer cure
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. This chart shows the profitability of the oncology sector. Its pipeline of drug candidates targets various tumor types. R&D costs impact current overall profitability, but the success of its research could lead to new treatment options for patients.
Overall market profit
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of cancer. Its value and prospects are determined solely by its research results and the potential of its pipeline. This chart illustrates general market trends, while Apollomics pursues its own scientific path, striving to develop new therapeutic approaches.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company focused on developing combination therapies for cancer. This chart reflects analysts' future earnings expectations based on the potential of its pipeline of drug candidates. It demonstrates the market's confidence that the company's synergistic approaches will prove effective in oncology.
%20profit%20of%20the%20company%20Apollomics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Apollomics-Inc.&v=1772578490027 "Graph of future (projected) profit of the company Apollomics Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing cancer treatments. This chart shows profitability projections for the oncology sector. It reflects expectations for the company's pipeline of developments targeting various tumor types and the overall investment climate in biotech.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772578490061 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Apollomics is a biopharmaceutical company specializing in oncology. For a company in the clinical development stage, market profit forecasts are important as an indicator of capital availability. During periods of economic optimism, investors are more willing to finance risky biotech projects, which is a key factor for Apollomics' future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772578490069 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Apollomics Inc.
Apollomics, Inc. is a biopharmaceutical company developing drugs to treat cancer. It is in the late clinical stage and preparing for commercialization. P/S will be a key metric after launch, reflecting how the market values its oncology drug portfolio.
P/S market segment - Cancer cure
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing combination therapies for cancer treatment targeting various oncogenic pathways. Their goal is to overcome treatment resistance. The chart demonstrates the market's confidence in their scientific approach and the potential of their oncology drug pipeline.
P/S of the market as a whole
Apollomics is a biotech company developing cancer treatments. The company has no commercial revenue, and its value is based on the potential of its clinical programs. This chart, showing the valuation of companies with real revenues, highlights the speculative nature of clinical-stage biotech investments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Apollomics Inc.
Apollomics, Inc. is a biopharmaceutical company developing drugs to treat cancer, often in combination with other therapies. This chart reflects investor expectations for future revenue from its oncology portfolio, which depend on the success of its clinical programs and its ability to find a niche in a highly competitive market.
%20P%2FS%20Apollomics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Apollomics-Inc.&v=1772578490283 "The graph of the company's future (projected) P/S Apollomics Inc.")
Future (projected) P/S of the market segment - Cancer cure
Apollomics, Inc. is a clinical-stage biopharmaceutical company developing combination therapies for cancer. This chart shows how the market perceives the future commercial potential of its oncology drug portfolio. It compares it to other cancer treatment companies, reflecting confidence in its scientific approach and clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772578490308 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Apollomics is a biopharmaceutical company developing cancer treatments, focusing on the US and Chinese markets. Its pipeline includes several promising candidates. This chart reflects overall sales expectations, and APLM demonstrates how global biotech companies are pursuing innovative treatments for the world's largest markets.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772578490321 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Apollomics Inc.
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on developing combination therapies for the treatment of cancer. Because its drugs are in development, the company has no sales revenue. Any revenue reflected in this chart likely comes from licensing or partnership agreements.
Sales of companies in the market segment - Cancer cure
Apollomics is a clinical-stage biotech company focused on developing cancer treatments. At this stage, its revenue, if any, may come from licensing agreements with partners. This chart allows investors to assess the financial support that is essential to its research.
Overall market sales
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Like other companies in this sector, its value is determined by clinical trial success. This overall economic activity chart bears no relation to the scientific progress that drives Apollomics.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancer. Its revenue forecast is based entirely on expectations of future clinical trial success. This chart reflects analysts' speculative valuation of its oncology drug portfolio.
%20sales%20of%20the%20company%20Apollomics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Apollomics-Inc.&v=1772578490429 "Schedule of future (projected) sales of the company Apollomics Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Apollomics is a clinical-stage biopharmaceutical company developing drugs for the treatment of oncology. This chart displays projected revenue for the entire oncotherapy segment. It provides an estimate of how quickly analysts expect this market to grow, which is critical to Apollomics' future commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772578490489 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Apollomics is a clinical-stage biopharmaceutical company developing cancer treatments. Its value is determined by the potential of its scientific developments. This chart of overall market expectations reflects investor risk appetite, which is critical for funding long-term and capital-intensive projects in the oncology biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772578490554 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company developing cancer treatments. This chart reflects its current focus on research. It doesn't show profits, but rather the effectiveness of managing capital invested in clinical trials, the success of which determines the company's entire future value.
Market segment marginality - Cancer cure
Apollomics, Inc. is a biopharmaceutical company focused on the discovery and development of innovative anticancer drugs. This chart depicts the average profitability in the oncology sector. It serves as a benchmark for assessing the potential commercial value of Apollomics' portfolio of drugs targeting various cancer types if they are successfully brought to market.
Market marginality as a whole
Apollomics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of combination therapies for the treatment of cancer. This total revenue chart shows the current situation, while Apollomics operates within the logic of the future, where the success of a single clinical trial can lead to the creation of a new standard of care.
Employees in the company, segment and market as a whole
Number of employees in the company Apollomics Inc.
Apollomics is a clinical-stage biopharmaceutical company developing cancer treatments. The growth of its team of scientists and clinical trial specialists, which can be seen in the chart, is directly related to the progress of its oncology drug pipeline and the expansion of its trials.
Share of the company's employees Apollomics Inc. within the market segment - Cancer cure
Apollomics, Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology drugs. This chart highlights its scientific focus. It reflects the percentage of leading oncologists and researchers working on the development of next-generation targeted and immunotherapies for cancer treatment that Apollomics brings together.
Number of employees in the market segment - Cancer cure
Apollomics, Inc. is a biopharmaceutical company developing drugs to treat cancer. This chart shows employment in the oncology sector. The growing number of scientists and clinicians reflects the global increase in investment in the fight against cancer and the search for new drug combinations to overcome tumor resistance, a focus for Apollomics.
Number of employees in the market as a whole
Apollomics, Inc. is a biopharmaceutical company developing drugs to treat oncology. The fight against cancer attracts huge investments and the best scientific minds. This chart reflects overall employment, and the success of such companies is not only important for medicine but also contributes to the growth of the high-tech sector of the economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Apollomics Inc. (APLM)
Apollomics, Inc. is an oncology company, and its value is the potential of its R&D portfolio. This chart shows the enormous value the market places on each scientist working on a new cancer drug. It's a pure valuation of intellectual capital and future cash flows if successful.
%20of%20the%20company%20Apollomics%20Inc.%20(APLM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Apollomics-Inc.-APLM&v=1772578490852 "Chart of market capitalization per employee (in thousands of dollars) of the company Apollomics Inc. (APLM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Apollomics is a biopharmaceutical company specializing in oncology. Its market capitalization per employee, like that of many biotech companies, reflects the potential of its drug pipeline. A high value indicates that investors see significant commercial potential in its scientific developments.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772578490972 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Apollomics is a clinical-stage biopharmaceutical company specializing in cancer drug development. The company's entire value is derived from its research portfolio. This chart reflects investor expectations for the team's ability to successfully conduct clinical trials and bring new oncology drugs to market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772578491016 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Apollomics Inc. (APLM)
Apollomics is a clinical-stage biotech company developing a portfolio of cancer treatments. The company has no commercial products. This negative graph shows how much investor capital is "burned" for each scientist and physician conducting clinical trials of these cancer candidates.
%20Chart%20Apollomics%20Inc.%20(APLM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Apollomics-Inc.-APLM&v=1772578491037 "Company Profit Per Employee (in thousands of dollars) Chart Apollomics Inc. (APLM)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Apollomics, Inc. is a biopharmaceutical company developing innovative cancer treatments targeting novel oncogenic pathways. This chart illustrates the potential value of their research portfolio. It demonstrates the enormous profit potential of a successful drug developed by a small team of scientists, a key metric for investors in the oncology sector.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772578491065 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Apollomics, Inc. is a biopharmaceutical company developing oncology drugs, including inhibitors and immunotherapies. Like most biotech companies in the R&D stage, this chart reflects the "cost" of research. It shows how much the company invests in each employee to advance its oncology programs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772578491074 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Apollomics Inc. (APLM)
Apollomics, Inc. is a clinical-stage oncology company. This chart does not reflect current commercial activity, as revenue is either nonexistent or minimal. It illustrates the R&D investment phase. Successful drug launches will lead to exponential growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Apollomics-Inc.-APLM&v=1772578491080 "Sales chart per company employee Apollomics Inc. (APLM)")
Sales per employee in the market segment - Cancer cure
Apollomics (APLM) is a biopharmaceutical company developing oncology drugs, with a focus on lung cancer and other solid tumors. This chart shows the average revenue per employee in the pharmaceutical segment. For Apollomics, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Apollomics (APLM) is a clinical-stage biotech company (oncology). Like other biotechs (CRIS, ADAP), there is no revenue from drug sales. This revenue is zero. The company's entire value lies in the potential of its R&D portfolio and the success of its clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Apollomics Inc. (APLM)
Apollomics is a clinical-stage biotech developing oncology drugs. The company has strong ties to China. This chart shows the odds on the failure of their developments. Bears may be concerned about both the risk of clinical failure and the geopolitical risks associated with their Chinese operations and partners.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Apollomics-Inc.-APLM&v=1772578491182 "Short Shares Chart for the Company Apollomics Inc. (APLM)")
Shares shorted by market segment - Cancer cure
Apollomics (APLM) is a biotech company developing cancer treatments focused on the Chinese market. This chart highlights the pessimism in the oncology sector. The growing short position in the industry is a bet that profits are impossible to make in China. Investors fear that even if APLM's drug is approved, the Chinese government will force it to be sold at near-cost, wiping out all profits.
Shares shorted by the overall market
Apollomics (APLM) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like APLM in order to move into safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Apollomics Inc. (APLM)
Apollomics is a biotech company focused on developing cancer drugs. It's one of many companies searching for the "holy grail" of oncology. This chart shows the feverish anticipation. It could remain overheated for a long time as investors bet on the success of their clinical programs, reflecting high speculative interest.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Apollomics-Inc.-APLM&v=1772578491266 "RSI 14 indicator chart for the company's stock Apollomics Inc. (APLM)")
RSI 14 Market Segment - Cancer cure
Apollomics is a clinical-stage biopharmaceutical company developing targeted oncology drugs (including c-Met inhibitors) for the treatment of cancer in the US and China. This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Apollomics (APLM) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APLM (Apollomics Inc.)
Apollomics is a biopharmaceutical company focused on developing next-generation targeted therapies for various types of cancer. This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APLM-Apollomics-Inc.&v=1772578491558 "A chart showing analyst consensus forecasts for the expected stock price. APLM (Apollomics Inc.)")
The difference between the consensus estimate and the actual stock price APLM (Apollomics Inc.)
Apollomics is a biopharmaceutical company developing a portfolio of targeted cancer drugs. This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see in their R&D pipeline and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APLM-Apollomics-Inc.&v=1772578491591 "A chart showing the difference between the consensus forecast and the actual stock price. APLM (Apollomics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Apollomics is a clinical-stage biotech developing targeted cancer therapies. This chart shows analysts' overall expectations for the oncology sector. It reflects whether experts believe in the company's R&D pipeline or believe the sector is overflowing with risky projects.
Analysts' consensus forecast for the overall market share price
Apollomics is a biotech company specializing in the development of drugs (immuno-oncology, targeted therapy) for cancer treatment, focusing on the US and Chinese markets. This chart shows the overall market "risk appetite." For Apollomics, operating in a high-risk sector with geopolitical risks (China), overall market optimism is important for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Apollomics Inc.
Apollomics is a clinical-stage biotech focused on developing next-generation targeted therapies for cancer (specifically lung and blood cancers). This chart is a pure indicator of confidence in their R&D. It doesn't reflect current sales, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Cancer cure
Apollomics (APLM) is a biopharmaceutical company developing innovative oncology drugs, often in partnership with other companies. Their portfolio includes inhibitors and immunotherapies for the treatment of various cancers. The chart shows the segment average index, helping investors assess how this discovery and development strategy compares to the industry average.
The AKIM Index for the overall market
Apollomics is a biopharmaceutical company developing cancer treatments, focusing on complex tumors and drug resistance. Its assets are located in the US and China. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this global oncology story fits in with overall economic trends.
